VI

Voyager Therapeutics, Inc.

www.voyagertherapeutics.com link_icon

Voyager Therapeutics Company Research Report



Company Overview



  • Name: Voyager Therapeutics, Inc.

  • Mission: To create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering to the right areas within the central nervous system.

  • Founded: No information is available.

  • Founder(s): No information is available.

  • Key People: Not explicitly mentioned in the data provided.

  • Headquarters: 75 Hayden Avenue, Lexington, MA 02421, USA

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • Known For: Voyager Therapeutics is known for leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. The company is recognized for its pipeline of genetic medicines for diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other central nervous system disorders.


Products



  • Product Offerings: Voyager Therapeutics offers genetic medicines targeting neurological diseases.

  • Anti-tau Antibody (VY7523): For Alzheimer's disease.

  • SOD1 Silencing Gene Therapy (VY9323) (siRNA): For ALS.

  • Tau Silencing Gene Therapy (siRNA): For Alzheimer's disease.

  • Anti-Aβ Gene Therapy (Vectorized Antibody): For Alzheimer's disease.


  • High-Level Product Descriptions:

  • Products are primarily derivatives of their TRACER™ AAV capsid discovery platform, which has revolutionized delivery across the blood-brain barrier.


  • Key Features:

  • The TRACER™ platform is known for its exceptional delivery of AAV capsids across the blood-brain barrier using non-human primate models.

  • Multiple modalities are employed including monoclonal antibodies and receptor-mediated non-viral delivery.


Recent Developments



  • Recent Developments:

  • As of 11.12.2024, Voyager Therapeutics reported its financial and operating results for the third quarter of 2024.

  • Voyager Therapeutics has presented at multiple investor conferences as of 11.06.2024.

  • They had announced a third-quarter 2024 conference call and webcast on 11.05.2024.


  • New Products Launched: No specific information on new products launched is available.

  • New Features Added to Existing Products: No specific updates on new features added to existing products are available.

  • New Partnerships:

  • Voyager has partnerships involving gene therapy for Friedreich’s Ataxia and Parkinson’s/other diseases through arrangements with Neurocrine, with options to co-commercialize.

  • Capsid licenses include collaborations with Alexion, AstraZeneca, and Novartis for diseases like rare neurological conditions and Prion Disease, as well as an ongoing agreement with Sangamo.


Additional Information



  • SCIENCE: Voyager's TRACER™ platform is a broad RNA-based screening system designed for accelerated discovery of AAV capsids with enhanced CNS tropism.

  • CORE VALUES: Include "Patients First," "Better Together," "Transformative Innovation," and "Disciplined Execution." The company is dedicated to putting patient needs first, acting with urgency due to the demand for transformative treatments.


This structured report delivers insight into Voyager Therapeutics, highlighting its mission, product pipeline, and recent developments while noting areas where more information could further structure the analysis.